RT Journal Article SR Electronic T1 Group IIA Secreted Phospholipase A2 Plays a Central Role in the Pathobiology of COVID-19 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.02.22.21252237 DO 10.1101/2021.02.22.21252237 A1 Justin M. Snider A1 Jeehyun Karen You A1 Xia Wang A1 Ashley J Snider A1 Brian Hallmark A1 Michael C. Seeds A1 Susan Sergeant A1 Laurel Johnstone A1 Qiuming Wang A1 Ryan Sprissler A1 Hao Helen Zhang A1 Chiara Luberto A1 Richard R. Kew A1 Yusuf A Hannun A1 Charles E. McCall A1 Guang Yao A1 Maurizio Del Poeta A1 Floyd H. Chilton YR 2021 UL http://medrxiv.org/content/early/2021/02/23/2021.02.22.21252237.abstract AB There is an urgent need to identify cellular and molecular mechanisms responsible for severe COVID-19 disease accompanied by multiple organ failure and high mortality rates. Here, we performed untargeted/targeted lipidomics and focused biochemistry on 127 patient plasma samples, and showed high levels of circulating, enzymatically active secreted phospholipase A2 Group IIA (sPLA2-IIA) in severe and fatal COVID-19 disease compared with uninfected patients or mild illness. Machine learning demonstrated that sPLA2-IIA effectively stratifies severe from fatal COVID-19 disease. We further introduce a PLA-BUN index that combines sPLA2-IIA and blood urea nitrogen (BUN) threshold levels as a critical risk factor for mitochondrial dysfunction, sustained inflammatory injury and lethal COVID-19. With the availability of clinically tested inhibitors of sPLA2-IIA, our study opens the door to a precision intervention using indices discovered here to reduce COVID-19 mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the following grants from the National Institutes of Health: R01 AT008621 (FHC), R35 GM126922 (CEM), AI125770 (MD),AI136934 (MD), and P01-CA97132 (YAH). This work was also supported by the Veterans Affairs Merit Review Grant I01BX002924 (MD) and the Technology and Research Initiative Fund (BIO5 Institute, University of Arizona, FHC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the central institutional review board at Stony Brook University (IRB2020-00423).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, FHC, upon request after publication of the manuscript.